Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2007; 98(01): 8-15
DOI: 10.1160/TH07-05-0343
DOI: 10.1160/TH07-05-0343
Anniversary Issue Contribution
Thrombosis and haemostasis research: Stimulating, hard work and fun
Further Information
Correspondence to:
Margareta Blombäck
Dept. of Molecular Medicine and Surgery
Karolinska Institutet
Clin. Chem. Build. L205
Karolinska University Hospital
Stockholm, 17177 Sweden
Phone: +46 8 5177 4437
Fax: +46 8 312 438
Email: margareta.blomback@ki.se
Publication History
Received
12 May 2007
Accepted
21 May 2007
Publication Date:
29 November 2017 (online)
MissingLinkText
-
References
- 1 Mutt V, Blombäck M. Erik Jorpes-a pragmatic physiological clinical chemist. Selected topics in the History of Biochemistry: Personal Recollections VI. Compr Biochem 2000; 41: 363-389.
- 2 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-443.
- 3 Blombäck B. Travels with fibrinogen. J Thromb Haemost 2006; 4: 1653-1660.
- 4 Blombäck B. Chapter 6: Journey with bleeding time factor. In: Stories of success. Personal Recollections. Compr Biochem. Vol. 45 211-258 Elsevier Science BV; 2008
- 5 Blombäck B. Studies on fibrinogen: its purification and conversion into fibrin. Acta Physiol Scand 1958; 43 (Suppl. 148) 1-51.
- 6 http://www.ki.se/essaer200ar/forfattarsidor/m_blomback/m_blomback_pres.htm http://www.ki.seessaer200ar/forfattarsidor/m_blomback/m_blomback_essa_s1a.htm http://www.ki.se/essaer200ar/forfattarsidor/m_blomback/m_blomback_essa_s1b.htm
- 7 Blombäck M. Purification of antihemophilic globulin. I. Some studies on the stability of the antihemophilic globulin activity in fraction I-0 and a method for its partial separation from fibrinogen. Arkiv Kemi 1958; 12: 387-396.
- 8 Blombäck M. Studies on antihemophilic globulin. Acta Paediatrica 1958; 47 (Suppl114) 1-32.
- 9 Nilsson IM, Blombäck M, Blombäck B. von Willebrand’s disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 1959; 164: 263-278.
- 10 Nilsson IM, Blombäck M, von Francken I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med. Scand. 1957; 159: 35-57.
- 11 Blombäck M. Scientific visits to the Åland Islands. Haemophilia, 1999; 5 (Suppl. 02) 12-18.
- 12 Blombäck M, Blombäck B, Nilsson IM. Response to fractions in von Willebrand’s disease. The Hemophilicas University North Carolina Press; Chapel Hill: 1964. pp. 286-294.
- 13 von Willebrand EA. “Hereditär pseudohämofili”. Finska Läkaresällskapets Handlingar 1926; 67: 87-111.
- 14 Nilsson IM, Blombäck M, Jorpes E. et al. von Willebrand’s disease and its correction with human plasma fraction I-O. Acta Med Scand 1957; 159: 179-188.
- 15 Blombäck M. A human factor VIII concentrate (Fraction I-0). Handbook of Hemophilia. Chapter 33. Excerpta Medica. Amsterdam: 1975. pp. 493-512.
- 16 Blombäck M, Nilsson IM. Treatment of hemophilia A with human antihemophilic globulin. Acta Med Scand 1958; 161: 301-321.
- 17 Nilsson IM, Blombäck M, Ramgren O. et al. Haemophilia in Sweden. II. Carriers of Haemophilia A and B. Acta Med Scand 1962; 171: 223-235.
- 18 Nilsson IM, Blombäck M, Ahlberg Å. Our experience in Sweden with prophylaxis on haemophilia. The Hemophiliacand his world. Proc Vth Congr Wld Fed Haemophilia. Montreal Bibl Haemat 1970; 34: 111-124.
- 19 Blombäck B. “Pehr Victor Edman: The solitary genius”. In: Selected topics in thehistory of Biochemistry: Personal Recollections VII. Compr Biochem 2003; 42: 103-135.
- 20 Blombäck B, Blombäck M, Gröndahl NJ. et al. Structure of fibrinopeptides - its relation to enzyme specificity and phylogeny and classification of species. Arkiv Kemi 1966; 25: 411-428.
- 21 Blombäck M, Blombäck B, Mammen EF. et al. Fibrinogen Detroit - a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218: 134-137.
- 22 Blombäck B, Blombäck M, Olsson P. et al. Synthetic peptides with anticoagulant and vasodilating activity. Scand Clin Lab Invest 1969; 107 (Suppl): 59-64.
- 23 Blombäck B, Blombäck M, Olsson P. et al. Förfarande för framställning av polypeptider med biologiska verkningar. Swedish Patent Application No 14557/67.
- 24 Svendsen L, Blombäck B, Blombäck M. et al. Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thromb Res 1972; 1: 267-278.
- 25 Blombäck M, Blombäck B, Claeson G. et al. Nya diagnostiskt användbara substrat med hög specificitet till trombinoch andra proteolytiska enzymer av typen peptidyl-peptid hydrolaser. Swedish Patent Application No 5757/72.
- 26 Blombäck M, Egberg N. Chromogenic peptide substrates in the laboratory diagnosis of clotting disorders. Haemostasis and Thrombosis. Edinburgh: Vol56, pp. 967-981 1986. 1987.
- 27 New Frontiers in Hemophilia Research XVth World Federation of Hemophilia Congress, Stockholm 1983. Scand J Haematology 1984; 33 (Suppl): 40.
- 28 Thorell L, Blombäck B. Purification of the factor VIII complex. Thromb Res 1984; 35: 431-450.
- 29 Hessel B, Jörnvall H, Thorell L. et al. Structure-function relationship of factor VIII complex studied by thioredoxin dependent disulfide reduction. Thromb Res 1984; 35: 637-651.
- 30 Thorell L, Blombäck M, Blombäck B. An in vivo study of a new factor VIII high purity preparation. Thromb Res 1983; 31: 375-385.
- 31 Heimburger N. Advances in hemophilia treatment: a hepatitis-safe factor VIII concentrate. Blut 1982; 44: 249-251.
- 32 Anvret M, Blombäck M, Lindstedt M. et al. Genetic and coagulation characterization of Swedish families with von Willebrand’s disease types I and III: New aspects of heredity. Human Genetics 1992; 89: 147-154.
- 33 Zhang ZP, Falk G, Blombäck M. et al. A single cytosine deletion in exon 18 of the von Willebrand factor geneis the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 1: 767-768.
- 34 Zhang ZP, Lindstedt M, Falk G. et al. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand’s disease type III and I. Am J Hum Genet 1992; 51: 870-878.
- 35 Zhang Z. Characterization of the von Willebrand factor gene in von Willebrand disease types 1 and 3. Thesis, Karolinska Institutet 1995.
- 36 Nyman D, Eriksson AW, Blombäck M. et al. Recent investigations of the first bleeder family in Åland (Finland) described by von Willebrand. Thromb Haemost 1981; 45: 73-76.
- 37 Zhang ZP, Blombäck M, Nyman D. et al. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Åland Islands. Proc Natl Acad Sci USA 1993; 90: 7937-7940.
- 38 Blombäck B, Carlsson K, Fatah K. et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
- 39 Fatah K, Hamsten A, Blombäck B. et al. Fibrin gel network characteristics and coronary heart disease: Relations to fibrinogen concentration, acute phaseprotein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
- 40 Williams S, Fatah K, Hjemdahl P. et al. Better increase in fibrin gel porosity by lowdose than intermediate dose acetylic acid. Eur Heart J 1998; 19: 1666-1672.
- 41 Gustafsson D, Bylund R, Antonsson T. et al. A new oral anticoagulant: the 50 year challenge. Nature Rev/ Drug Discov 2004; 3: 649-658.
- 42 Li N, He S, Blombäck M. et al. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscl Thromb Vasc Biol 2007; 27: 407-413.
- 43 Suontaka AM. Hemostatic changes in plasma for transfusion during preparation and storage. Thesis, Karolinska Institutet, Stockholm, Sweden 2006.
Correspondence to:
Margareta Blombäck
Dept. of Molecular Medicine and Surgery
Karolinska Institutet
Clin. Chem. Build. L205
Karolinska University Hospital
Stockholm, 17177 Sweden
Phone: +46 8 5177 4437
Fax: +46 8 312 438
Email: margareta.blomback@ki.se
-
References
- 1 Mutt V, Blombäck M. Erik Jorpes-a pragmatic physiological clinical chemist. Selected topics in the History of Biochemistry: Personal Recollections VI. Compr Biochem 2000; 41: 363-389.
- 2 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-443.
- 3 Blombäck B. Travels with fibrinogen. J Thromb Haemost 2006; 4: 1653-1660.
- 4 Blombäck B. Chapter 6: Journey with bleeding time factor. In: Stories of success. Personal Recollections. Compr Biochem. Vol. 45 211-258 Elsevier Science BV; 2008
- 5 Blombäck B. Studies on fibrinogen: its purification and conversion into fibrin. Acta Physiol Scand 1958; 43 (Suppl. 148) 1-51.
- 6 http://www.ki.se/essaer200ar/forfattarsidor/m_blomback/m_blomback_pres.htm http://www.ki.seessaer200ar/forfattarsidor/m_blomback/m_blomback_essa_s1a.htm http://www.ki.se/essaer200ar/forfattarsidor/m_blomback/m_blomback_essa_s1b.htm
- 7 Blombäck M. Purification of antihemophilic globulin. I. Some studies on the stability of the antihemophilic globulin activity in fraction I-0 and a method for its partial separation from fibrinogen. Arkiv Kemi 1958; 12: 387-396.
- 8 Blombäck M. Studies on antihemophilic globulin. Acta Paediatrica 1958; 47 (Suppl114) 1-32.
- 9 Nilsson IM, Blombäck M, Blombäck B. von Willebrand’s disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 1959; 164: 263-278.
- 10 Nilsson IM, Blombäck M, von Francken I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med. Scand. 1957; 159: 35-57.
- 11 Blombäck M. Scientific visits to the Åland Islands. Haemophilia, 1999; 5 (Suppl. 02) 12-18.
- 12 Blombäck M, Blombäck B, Nilsson IM. Response to fractions in von Willebrand’s disease. The Hemophilicas University North Carolina Press; Chapel Hill: 1964. pp. 286-294.
- 13 von Willebrand EA. “Hereditär pseudohämofili”. Finska Läkaresällskapets Handlingar 1926; 67: 87-111.
- 14 Nilsson IM, Blombäck M, Jorpes E. et al. von Willebrand’s disease and its correction with human plasma fraction I-O. Acta Med Scand 1957; 159: 179-188.
- 15 Blombäck M. A human factor VIII concentrate (Fraction I-0). Handbook of Hemophilia. Chapter 33. Excerpta Medica. Amsterdam: 1975. pp. 493-512.
- 16 Blombäck M, Nilsson IM. Treatment of hemophilia A with human antihemophilic globulin. Acta Med Scand 1958; 161: 301-321.
- 17 Nilsson IM, Blombäck M, Ramgren O. et al. Haemophilia in Sweden. II. Carriers of Haemophilia A and B. Acta Med Scand 1962; 171: 223-235.
- 18 Nilsson IM, Blombäck M, Ahlberg Å. Our experience in Sweden with prophylaxis on haemophilia. The Hemophiliacand his world. Proc Vth Congr Wld Fed Haemophilia. Montreal Bibl Haemat 1970; 34: 111-124.
- 19 Blombäck B. “Pehr Victor Edman: The solitary genius”. In: Selected topics in thehistory of Biochemistry: Personal Recollections VII. Compr Biochem 2003; 42: 103-135.
- 20 Blombäck B, Blombäck M, Gröndahl NJ. et al. Structure of fibrinopeptides - its relation to enzyme specificity and phylogeny and classification of species. Arkiv Kemi 1966; 25: 411-428.
- 21 Blombäck M, Blombäck B, Mammen EF. et al. Fibrinogen Detroit - a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218: 134-137.
- 22 Blombäck B, Blombäck M, Olsson P. et al. Synthetic peptides with anticoagulant and vasodilating activity. Scand Clin Lab Invest 1969; 107 (Suppl): 59-64.
- 23 Blombäck B, Blombäck M, Olsson P. et al. Förfarande för framställning av polypeptider med biologiska verkningar. Swedish Patent Application No 14557/67.
- 24 Svendsen L, Blombäck B, Blombäck M. et al. Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes. Thromb Res 1972; 1: 267-278.
- 25 Blombäck M, Blombäck B, Claeson G. et al. Nya diagnostiskt användbara substrat med hög specificitet till trombinoch andra proteolytiska enzymer av typen peptidyl-peptid hydrolaser. Swedish Patent Application No 5757/72.
- 26 Blombäck M, Egberg N. Chromogenic peptide substrates in the laboratory diagnosis of clotting disorders. Haemostasis and Thrombosis. Edinburgh: Vol56, pp. 967-981 1986. 1987.
- 27 New Frontiers in Hemophilia Research XVth World Federation of Hemophilia Congress, Stockholm 1983. Scand J Haematology 1984; 33 (Suppl): 40.
- 28 Thorell L, Blombäck B. Purification of the factor VIII complex. Thromb Res 1984; 35: 431-450.
- 29 Hessel B, Jörnvall H, Thorell L. et al. Structure-function relationship of factor VIII complex studied by thioredoxin dependent disulfide reduction. Thromb Res 1984; 35: 637-651.
- 30 Thorell L, Blombäck M, Blombäck B. An in vivo study of a new factor VIII high purity preparation. Thromb Res 1983; 31: 375-385.
- 31 Heimburger N. Advances in hemophilia treatment: a hepatitis-safe factor VIII concentrate. Blut 1982; 44: 249-251.
- 32 Anvret M, Blombäck M, Lindstedt M. et al. Genetic and coagulation characterization of Swedish families with von Willebrand’s disease types I and III: New aspects of heredity. Human Genetics 1992; 89: 147-154.
- 33 Zhang ZP, Falk G, Blombäck M. et al. A single cytosine deletion in exon 18 of the von Willebrand factor geneis the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 1: 767-768.
- 34 Zhang ZP, Lindstedt M, Falk G. et al. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand’s disease type III and I. Am J Hum Genet 1992; 51: 870-878.
- 35 Zhang Z. Characterization of the von Willebrand factor gene in von Willebrand disease types 1 and 3. Thesis, Karolinska Institutet 1995.
- 36 Nyman D, Eriksson AW, Blombäck M. et al. Recent investigations of the first bleeder family in Åland (Finland) described by von Willebrand. Thromb Haemost 1981; 45: 73-76.
- 37 Zhang ZP, Blombäck M, Nyman D. et al. Mutations of von Willebrand factor gene in families with von Willebrand disease in the Åland Islands. Proc Natl Acad Sci USA 1993; 90: 7937-7940.
- 38 Blombäck B, Carlsson K, Fatah K. et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
- 39 Fatah K, Hamsten A, Blombäck B. et al. Fibrin gel network characteristics and coronary heart disease: Relations to fibrinogen concentration, acute phaseprotein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
- 40 Williams S, Fatah K, Hjemdahl P. et al. Better increase in fibrin gel porosity by lowdose than intermediate dose acetylic acid. Eur Heart J 1998; 19: 1666-1672.
- 41 Gustafsson D, Bylund R, Antonsson T. et al. A new oral anticoagulant: the 50 year challenge. Nature Rev/ Drug Discov 2004; 3: 649-658.
- 42 Li N, He S, Blombäck M. et al. Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: effects of thrombin inhibition by argatroban and enoxaparin. Arterioscl Thromb Vasc Biol 2007; 27: 407-413.
- 43 Suontaka AM. Hemostatic changes in plasma for transfusion during preparation and storage. Thesis, Karolinska Institutet, Stockholm, Sweden 2006.